Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Through the Mango partnership, Veeda will use the AI company’s Querent platform to streamline procedures, improve data management and increase diversity of research participants, according to a July 8 ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. | KJ ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Cargo will mark the latest in a string of acquisitions for the deal-hungry Concentra. So far this year, Concentra has signed ...